Compare FPI & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FPI | EYPT |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.2M | 1.5B |
| IPO Year | 2013 | 2005 |
| Metric | FPI | EYPT |
|---|---|---|
| Price | $11.09 | $12.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $31.80 |
| AVG Volume (30 Days) | 577.7K | ★ 1.2M |
| Earning Date | 05-06-2026 | 03-04-2026 |
| Dividend Yield | ★ 3.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $52,178,000.00 | $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,031.72 |
| P/E Ratio | $17.73 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.37 | $3.91 |
| 52 Week High | $13.23 | $19.11 |
| Indicator | FPI | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 37.40 | 36.03 |
| Support Level | $10.49 | $11.88 |
| Resistance Level | $11.15 | $13.32 |
| Average True Range (ATR) | 0.36 | 0.97 |
| MACD | -0.21 | -0.32 |
| Stochastic Oscillator | 14.35 | 11.68 |
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.